ArticleMikrochimica acta2026
Ultrasensitive electrochemical sensor for HBV DNA detection based on exo III + HCR cascade amplification and label-assisted signal enhancement.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An Ultrasensitive Electrochemical Biosensor for Nucleic Acid Detection Based on Silver Nanoflower-Stem-Loop Probes.Sensors (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hepatitis B virus (HBV) infection is a leading cause of cirrhosis and hepatocellular carcinoma worldwide, and HBV DNA serves as a key molecular biomarker for diagnosis and therapeutic monitoring. Accurate and ultrasensitive quantification of HBV DNA is therefore crucial for early detection and clinical management. Herein, we developed an electrochemical DNA biosensor that integrates Exonuclease III (Exo III)-assisted target recycling with a hybridization chain reaction (HCR)-based cascade amplification. Platinum-decorated cobalt-copper carbon nanocubes (CoCu/CNC/Pt) nanozymes were employed as signal labels to synergistically amplify electrochemical responses, enabling highly sensitive detection of HBV DNA. Target DNA undergoes Exo III-catalyzed cyclic cleavage, releasing trigger strands (sDNA) that initiate the HCR process, driving the alternating hybridization of two hairpin probes (DNA1 and DNA2) into extended double-helical networks. These supramolecular structures present multiple terminal single-stranded regions that hybridize with complementary CoCu/CNC/Pt/aDNA probes, facilitating efficient anchoring of nanozyme labels on the electrode surface. The CoCu/CNC/Pt nanocomposites provide abundant redox-active sites and exhibit excellent catalytic activity toward H
Indexed as
Identifiers
41498795What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.